BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Biota Holdings Limited (BTA.AX) Announces Approval of Definitive Merger Agreement by Nabi Biopharmaceuticals (NABI) Shareholders


10/23/2012 8:46:40 AM

MELBOURNE, AUSTRALIA--(Marketwire - October 23, 2012) - Biota Holdings Limited (ASX: BTA) (Biota) announces that the shareholders of Nabi Biopharmaceuticals Inc. (Nabi) have approved proposals related to the business combination transaction with Biota, at a shareholders meeting held at 4:30pm EDT on October 22, 2012 in Bethesda, MD.

As set out in the Explanatory Memorandum on August 6, 2012, Nabi shareholders were to vote on a number of proposals, including the following:

  • To increase the authorised shares in Nabi to 200,000,000;
  • To approve the issuance of shares of Nabi to Biota shareholders as contemplated by the Merger Implementation Agreement;
  • To approve, at Nabi directors' sole discretion, a share consolidation in the range of four-to-one to eight-to-one; and
  • To approve the change of name from Nabi Biopharmaceuticals to Biota Pharmaceuticals Inc.

Each of these proposals was approved by the requisite majority votes.

Biota shareholders will meet at 2:00pm on October 23, 2012 in Melbourne, Australia to approve the Revised Scheme of Arrangement in relation to the transaction. Shareholders unable to attend the meeting will be provided with results immediately upon conclusion.

About Biota

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has a well advanced program for human rhinovirus (HRV) infection with a completed Phase IIb study in asthmatic subjects.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza antivirals, of which the lead product lnavir®, is marketed in Japan. Biota holds a contract from the US Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of laninamivir in the USA.

Relenza™ is a registered trademark of the GlaxoSmithKline group of companies.
Inavir® is registered to Daiichi Sankyo.


Further information
Investor/Analyst Enquiries
Biota Holdings Limited
Peter Cook
T: +61 3 9915 3720
Damian Lismore
T: +61 3 9915 3721

Shareholder Enquiries
Biota Shareholder Information Line
T: 1300 306 230 (within Australia)
T: +61 2 8280 7169 (International)
Between 8:30am and 7:30pm
(Melbourne time)

Media Enquiries
Nerida Mossop
Hinton & Associates
T: +61 3 9600 1979
M: +61 437 361 433

Felicity Williams
Hinton & Associates
T: +61 3 9600 1979
M: +61 416 770 012

US Enquiries
Hershel Berry
Blueprint Life Science Group
M: +1 415.375.3340 Ext. 102



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->